These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 9241676)
1. Identifying teratogens: the tyranny of lists. Scialli AR Reprod Toxicol; 1997; 11(4):555-9. PubMed ID: 9241676 [No Abstract] [Full Text] [Related]
2. Methods of evaluating the alleged teratogenicity of environmental agents. Brent RL Prog Clin Biol Res; 1985; 163C():191-5. PubMed ID: 3991621 [No Abstract] [Full Text] [Related]
3. Making information work. Scialli AR Reprod Toxicol; 1990; 4(4):249-50. PubMed ID: 2136044 [No Abstract] [Full Text] [Related]
4. Teratology Society 1998 Public Affairs Committee Symposium: the new thalidomide era: dealing with the risks. Friedman JM; Kimmel CA Teratology; 1999 Feb; 59(2):120-3. PubMed ID: 10069442 [No Abstract] [Full Text] [Related]
5. Report of the Teratology Society Public Affairs Committee symposium on FDA classification of drugs. Friedman JM Teratology; 1993 Jul; 48(1):5-6. PubMed ID: 8102499 [No Abstract] [Full Text] [Related]
6. Human teratogens: update 2010. Holmes LB Birth Defects Res A Clin Mol Teratol; 2011 Jan; 91(1):1-7. PubMed ID: 21254353 [TBL] [Abstract][Full Text] [Related]
7. Reproductive and developmental toxicity testing: from in vivo to in vitro. Brown ES; Jacobs A; Fitzpatrick S ALTEX; 2012; 29(3):333-9. PubMed ID: 23019687 [No Abstract] [Full Text] [Related]
8. Isotretinoin prescribing: finding a balance between benefit and risk. Stern RS Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):611-3. PubMed ID: 16134100 [No Abstract] [Full Text] [Related]
9. FDA classification of drugs for teratogenic risk. Teratology Society Public Affairs Committee. Teratology; 1994 Jun; 49(6):446-7. PubMed ID: 7747265 [TBL] [Abstract][Full Text] [Related]
10. Teratology public affairs committee position paper: Pregnancy labeling for prescription drugs: Ten years later. Public Affairs Committee of the Teratology Society Birth Defects Res A Clin Mol Teratol; 2007 Sep; 79(9):627-30. PubMed ID: 17663419 [No Abstract] [Full Text] [Related]
11. Pregnancy categories for prescription drugs. FDA Drug Bull; 1982 Dec; 12(3):24-5. PubMed ID: 7166220 [No Abstract] [Full Text] [Related]
12. The importance of epidemiology in identifying drugs which may cause malformations--with particular reference to drugs containing sex hormones. Kelsey FO Acta Morphol Acad Sci Hung; 1980; 28(1-2):189-95. PubMed ID: 7004099 [No Abstract] [Full Text] [Related]
13. FDA perspectives on the use of teratology data for human risk assessment. Frankos VH Fundam Appl Toxicol; 1985 Aug; 5(4):615-25. PubMed ID: 3840107 [No Abstract] [Full Text] [Related]
14. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration. Kelsey FO Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617 [No Abstract] [Full Text] [Related]
15. Ethical and legal aspects of teratogenic medications: the case of isotretinoin. Moskop JC; Smith ML; De Ville K J Clin Ethics; 1997; 8(3):264-78. PubMed ID: 9436085 [No Abstract] [Full Text] [Related]